Today: Today, 116 Shares of Illumina Inc. (ILMN) Stock are sold by Charles Dadswell

Today, 116 Shares of Illumina Inc. (ILMN) Stock are sold by Charles Dadswell

Illumina Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 116 shares of the business’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $182.38, for a total transaction of $21,156.08. Following the completion of the sale, the senior vice president now directly owns 39,900 shares of the company’s stock, valued at approximately $7,276,962. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Charles Dadswell also recently made the following trade(s): On Wednesday, July 27th, Charles Dadswell sold 8,632 shares of Illumina stock. The shares were sold at an average price of $155.00, for a total transaction of $1,337,960.00.

Illumina Inc. (NASDAQ:ILMN) opened at 184.93 on Friday. Illumina Inc. has a 52 week low of $127.10 and a 52 week high of $196.47. The company’s 50-day moving average is $174.28 and its 200 day moving average is $156.11. The company has a market capitalization of $27.11 billion, a price-to-earnings ratio of 63.33 and a beta of 0.47.

10/07/charles-dadswell-sells-116-shares-of-illumina-inc-ilmn-stock.html

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. The business had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. Illumina’s quarterly revenue was up 11.3% on a year-over-year basis. During the same period last year, the firm posted $0.80 earnings per share. On average, analysts forecast that Illumina Inc. will post $3.53 EPS for the current fiscal year.

Several brokerages have recently commented on ILMN. Zacks Investment Research upgraded shares of Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. CL King cut shares of Illumina from a “buy” rating to a “neutral” rating in a research report on Monday, August 22nd. Piper Jaffray Cos. restated an “overweight” rating and issued a $161.00 target price on shares of Illumina in a research report on Friday, July 15th. Vetr upgraded shares of Illumina from a “sell” rating to a “buy” rating and set a $198.61 target price for the company in a research report on Monday. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $165.00 target price on shares of Illumina in a research report on Wednesday, July 27th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and twelve have given a buy rating to the stock. Illumina has a consensus rating of “Hold” and an average price target of $164.94.

Large investors have recently made changes to their positions in the stock. Temasek Holdings Private Ltd increased its stake in shares of Illumina by 163.2% in the first quarter. Temasek Holdings Private Ltd now owns 277,261 shares of the life sciences company’s stock worth $44,947,000 after buying an additional 171,900 shares in the last quarter. Douglas Lane & Associates LLC increased its stake in shares of Illumina by 3.2% in the second quarter. Douglas Lane & Associates LLC now owns 441,993 shares of the life sciences company’s stock worth $62,047,000 after buying an additional 13,639 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Illumina by 1.4% in the first quarter. Legal & General Group Plc now owns 593,016 shares of the life sciences company’s stock worth $96,134,000 after buying an additional 8,089 shares in the last quarter. Retirement Systems of Alabama increased its stake in shares of Illumina by 1.6% in the second quarter. Retirement Systems of Alabama now owns 189,245 shares of the life sciences company’s stock worth $26,566,000 after buying an additional 2,934 shares in the last quarter. Finally, IBM Retirement Fund increased its stake in shares of Illumina by 1.9% in the second quarter. IBM Retirement Fund now owns 19,137 shares of the life sciences company’s stock worth $2,768,000 after buying an additional 364 shares in the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Related posts

Leave a Comment